ReviewJournal of translational medicine2026
Diabetic retinopathy: why some eyes suffer more - a focus on retina-specific risk factors and metabolic memory.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic retinopathy (DR) is a significant microvascular complication of diabetes mellitus (DM) and remains the primary cause of vision loss among diabetic patients, imposing a severe burden on both quality of life and socioeconomic resources. Although hyperglycemia is established as the central driver for the onset and progression of DR, substantial heterogeneity in individual susceptibility exists, as not all patients with comparable diabetic status develop DR. This highlights the influence of additional specific modifying factors. Therefore, systematically elucidating the hierarchical framework of risk factors for DR, with particular emphasis on retina-specific mechanisms and the concept of “metabolic memory,” is crucial for achieving effective clinical risk stratification and formulating individualized prevention and management strategies.
methodsThis review is based on a systematic analysis of relevant clinical studies from over 20 countries published in the past five years. We synthesized the available evidence to construct a hierarchical framework of risk factors influencing DR development and summarized the key factors. The core driving role of DM and persistent hyperglycemia was first affirmed. We then elaborated on how multilayered modifying factors—encompassing genetic background, comorbid disease history, individual lifestyle choices, and alterations in physical/chemical indicators—synergistically or independently modulate DR risk and progression. Special attention was given to discussing the profound impact of “metabolic memory,” genetic susceptibility, and the unique role of the local retinal microenvironment.
conclusionThis review systematically confirms that DM and its persistent hyperglycemia constitute the indisputable initiator and pathological cornerstone of DR. Upon this foundation, a complex modifying network—formed by genetic predisposition, comorbidities (e.g., nephropathy, hypertension), individual lifestyle, inflammatory and metabolic disturbances, and the specificity of the retinal microenvironment—collectively and differentially regulates disease progression. Comprehending this hierarchical risk system, particularly acknowledging the long-term impact of early intensive glycemic control (“metabolic memory”) and the role of retina-specific pathways, is fundamental to enabling effective clinical risk stratification, early identification of high-risk individuals, and implementing multidisciplinary, precise interventions. Future research should further explore retina-specific metabolic, immune, and genetic mechanisms to propel the development of novel strategies for DR prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.